Abstract:2934 Breast cancer presents as estrogen receptor alpha (ERα) positive or negative. ERα- tumors have a poor prognosis, are resistant to hormonal therapies, and frequently show overexpression, amplification, and/or hyperactivation of growth factor receptors, such as the erbB family. Using cell line models that mimic this elevated growth factor signaling by EGFR and erbB-2 in MCF-7 breast cancer cells, we have previously shown that hyperactivation of downstream p42/44 MAPK results in the reversible loss of ERα expression, and that in addition to the direct effect of MAPK on ERα, indirect activation of NFkB by MAPK also plays a role. In this study, we set out to determine if the inihibition of MAPK activity in established ERα- breast cancer cell lines could restore ERα expression and further, if this re-expressed ERα could now restore anti-estrogen response. MAPK inhibition via treatment with U0126 in 3 ERα- breast cancer cell lines, the EGFR overexpressing SUM 229s, the EGFR/c-erbB-2 dual overexperssing SUM 190s, and the RhoC overexpressing SUM 149s resulted in the sustained re-expression of ERα protein in all 3 cell lines. To ascertain that this re-expressed ERα could now restore anti-estrogen sensitivity, growth assays analyzing the effects of 4-hydroxy-tamoxifen (4HT) and the pure antiestrogen ICI 182,780 (faslodex) at 10-7 M alone, 5 μM U0126 alone, or the combination of 4HT or ICI and U0126 on cell proliferation were performed by WST-1 assay. ERα- SUM 229 and 149 cells were resistant to both 4HT and ICI. While having no growth inhibitory effects on its own, 5 μM U016 restored the growth inhibitory effects of both 4HT and ICI in ERα- SUM 229 cells, but not in SUM 149 cells. To determine if these in vitro cell line results would extrapolate to a real breast tumor situation, ERα- tumor specimens were obtained from the Tissue Procurement Core. Tumors were minced and divided evenly into a baseline sample and into tissue culture dishes containing medium alone, or supplemented with 10 μM U0126 or vehicle control DMSO. The minced tumor specimens in medium plus or minus U0126 were incubated at 37oC/5%CO2 for 20 hours. RNA was prepared from all treatment groups and analyzed for ERα mRNA level by qRT-PCR. Of the 12 tumors received to date, 6 displayed increased ERα mRNA levels after treatment with U0126. Collectively, these data are supportive of our hypothesis that there exists a population of ERα- tumors where upregulated growth factor signaling is directly involved in the generation of the ERα- phenotype by repressing ERα expression. Importanly, these data suggest that this reversible downregulation may be targeted clinically such that this repression can be reversed by inhibiting signaling through MAPK, resulting in re-expression of ERα and perhaps restoration of tamoxifen sensitivity.

KLF6 inhibits estrogen receptor-mediated cell growth in breast cancer via a c-Src-mediated pathway

KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer

Abstract A46: KLF4 Overcomes Tamoxifen Resistance by Suppressing MAPK Signaling Pathway in Breast Cancer

Estrogen-Induced Interaction Between Klf5 And Estrogen Receptor (Er) Suppresses The Function Of Er In Er-Positive Breast Cancer Cells

KLF4 Downregulates Htert Expression and Telomerase Activity to Inhibit Lung Carcinoma Growth.

KRAB-containing Zinc Finger Protein ZNF496 Inhibits Breast Cancer Cell Proliferation by Selectively Repressing ERα Activity.

ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer

Kruppel-Like Factor 6 Suppresses Growth and Invasion of Hepatocellular Carcinoma Cells in Vitro and in Vivo

Sphingosine Kinase (sphk) Mediates Transactivation of the Epidermal Growth Factor Receptor (egfr) by Estrogen in Breast Cancer Cells

Regulation of KLF4 by Posttranslational Modification Circuitry in Endocrine Resistance.

Keratin 18 Attenuates Estrogen Receptor Α-Mediated Signaling by Sequestering LRP16 in Cytoplasm

KLF5 Promotes Breast Cell Survival Partially Through Fibroblast Growth Factor-Binding Protein 1-Perk-mediated Dual Specificity MKP-1 Protein Phosphorylation and Stabilization.

Krüppel-Like Factor 6 Downregulation Is Connected with a Poor Prognosis and Tumor Growth in Non-Small-Cell Lung Cancer

Silencing of kallikrein-related peptidase 6 attenuates the proliferation, migration, and invasion of gastric cancer cells through inhibition of epithelial-mesenchymal transition

RETRACTED: Kruppel-Like Factor 6 Downregulation is Connected with a Poor Prognosis and Tumor Growth in Non-Small-Cell Lung Cancer (retracted Article)

Krüppel-like Factor 5 Promotes Breast Cell Proliferation Partially Through Upregulating the Transcription of Fibroblast Growth Factor Binding Protein 1.

Kruppel-like factor 9 upregulates E-cadherin transcription and represses breast cancer invasion and metastasis

Novel Insight into KLF4 Proteolytic Regulation in Estrogen Receptor Signaling and Breast Carcinogenesis

The Clinical Relevance and Function of Krüppel-Like Factor 16 in Breast Cancer.

Krupple-Like Factor 5 Promotes Breast Cancer Proliferation Through Activating Fibroblast Growth Factor-Binding Protein Transcription

KLF15 Suppresses Tumor Growth and Metastasis in Triple-Negative Breast Cancer by Downregulating CCL2 and CCL7.